| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fca31e40a2462d93d4c37babd7834834
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd2fa7f4cb06b2d242373a52f00d506b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c8794ef24f8f452d9c08389b03363c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7fddbb951647c0cddea33f6c6b46ba5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ecf8a810c7e70ab56f28695efd814da |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate |
2007-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_facc9d441a1a6e57171e07f668b8755f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa85c5d16e0cafaaf645b2ebd7d99857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1491e7798dd307d8c07a187ab4f93c77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55cf7c32fa1dd08e364a8ded2c7dbd94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8cc004738ff390ea9c62330d2b4e592 |
| publicationDate |
2007-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007126336-A1 |
| titleOfInvention |
Agent exhibiting immunoregulatory properties and the use thereof for treating autoimmune diseases |
| abstract |
The invention relates to medicine. The inventive agent which exhibits immunoregulatory properties and accelerated clinical performance at a recrudescence stage and is mainly used for treating autoimmune diseases comprises trophoblastic β-1-glycoprotein and immunoglobulin (Ig) which is embodied in the form of a multivalent ligand G (Ig-G) or A (Ig-A) or M (Ig-M) immunoglobulin. According to the second invention, an agent for treating autoimmune diseases comprises β-1-glycoprotein and immunoglobulin (Ig-G), wherein the multivalent ligand G or A (Ig-A) is used in the form of an immunoglobulin and the β-1-glycoprotein and immunoglobulin (Ig-G) are taken in equal portions on in portions whose ratio is equal to 1:19, respectively. For treating autoimmune diseases, the agent containing β-1-glycoprotein and immunoglobulin (Ig) is parenterally administratable. |
| priorityDate |
2006-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |